1. Arsuaga-Zorilla CB, Grooters AM, Pucheu-Haston CM. Quantitation of anti-Pythium insidiosum antibodies before and after administration of an immunotherapeutic product to healthy dogs. Am J Vet Res 2018;79:1160–1165.
2. Iněz-Ferreira TM, Mendoza L, Vilela R, et al. A Leishmania murine model to evaluate the immunotherapeutic properties of Pythium insidiosum proteins. Heliyon 2017;3:e00278.
3. Bach BC, Leal DB, Ruchel JB, et al. Immunotherapy for pythiosis: effect on NTPDase activity in lymphocytes of an experimental model. Biomed Pharmacother 2010;64:718–722.
4. Bach BC, Leal DB, Jaques JA, et al. E-ADA activity in lymphocytes of an experimental model of pythiosis treated with immunotherapy. Cell Biochem Funct 2013;31:476–481.
5. Ledur PC, Tondolo JSM, Jesus FPK et al. Dendritic cells pulsed with Pythium insidiosum (1,3)(1,6)-γ-glucan, heat-inactivated zoospores and immunotherapy prime naïve T cells to Th1 differentiation in vitro. Immunobiology 2018;223:294–299.
6. Weiblen C, Zanette RA, Ribeiro TC et al. Intradermal injection of Pythium insidiosum protein antigens for improved diagnosis and treatment of pythiosis in an experimental model [published online ahead of print Sep 26, 2018]. Med Mycol doi: 10.1093/mmy/myy078.
7. Mendoza L, Villalobos J, Calleja CE, et al. Evaluation of two vaccines for the treatment of pythiosis insidosi in horses. Mycopathologia 1992;119:89–95.
1. Bach BC, Leal DB, Jaques JA, et al. E-ADA activity in lymphocytes of an experimental model of pythiosis treated with immunotherapy. Cell Biochem Funct 2013;31:476–481.
2. Bach BC, Leal DB, Ruchel JB, et al. Immunotherapy for pythiosis: effect on NTPDase activity in lymphocytes of an experimental model. Biomed Pharmacother 2010;64:718–722.
3. Inez-Ferreira TM, Mendoza L, Vilela R, et al. A Leishmania murine model to evaluate the immunomodulatory properties of Pythium insidiosum proteins. Heliyon 2017;3:e00278.
4. Ledur PC, Tondolo JSM, Jesus FPK, et al. Dendritic cells pulsed with Pythium insidiosum (1,3)(1,6)-beta-glucan, heat-inactivated zoospores and immunotherapy prime naive T cells to Th1 differentiation in vitro. Immunobiology 2018;223:294–299.
5. Weiblen C, Zanette RA, Ribeiro TC, et al. Intradermal injection of Pythium insidiosum protein antigens for improved diagnosis and treatment of pythiosis in an experimental model [published online ahead of print Sep 26, 2018]. Med Mycol doi: 10.1093/mmy/myy078.
6. Santurio JM, Leal AT, Leal AB, et al. Three types of immunotherapics against pythiosis insidiosi developed and evaluated. Vaccine 2003;21:2535–2540.
Advertisement
1. Arsuaga-Zorilla CB, Grooters AM, Pucheu-Haston CM. Quantitation of anti-Pythium insidiosum antibodies before and after administration of an immunotherapeutic product to healthy dogs. Am J Vet Res 2018;79:1160–1165.
2. Iněz-Ferreira TM, Mendoza L, Vilela R, et al. A Leishmania murine model to evaluate the immunotherapeutic properties of Pythium insidiosum proteins. Heliyon 2017;3:e00278.
3. Bach BC, Leal DB, Ruchel JB, et al. Immunotherapy for pythiosis: effect on NTPDase activity in lymphocytes of an experimental model. Biomed Pharmacother 2010;64:718–722.
4. Bach BC, Leal DB, Jaques JA, et al. E-ADA activity in lymphocytes of an experimental model of pythiosis treated with immunotherapy. Cell Biochem Funct 2013;31:476–481.
5. Ledur PC, Tondolo JSM, Jesus FPK et al. Dendritic cells pulsed with Pythium insidiosum (1,3)(1,6)-γ-glucan, heat-inactivated zoospores and immunotherapy prime naïve T cells to Th1 differentiation in vitro. Immunobiology 2018;223:294–299.
6. Weiblen C, Zanette RA, Ribeiro TC et al. Intradermal injection of Pythium insidiosum protein antigens for improved diagnosis and treatment of pythiosis in an experimental model [published online ahead of print Sep 26, 2018]. Med Mycol doi: 10.1093/mmy/myy078.
7. Mendoza L, Villalobos J, Calleja CE, et al. Evaluation of two vaccines for the treatment of pythiosis insidosi in horses. Mycopathologia 1992;119:89–95.
1. Bach BC, Leal DB, Jaques JA, et al. E-ADA activity in lymphocytes of an experimental model of pythiosis treated with immunotherapy. Cell Biochem Funct 2013;31:476–481.
2. Bach BC, Leal DB, Ruchel JB, et al. Immunotherapy for pythiosis: effect on NTPDase activity in lymphocytes of an experimental model. Biomed Pharmacother 2010;64:718–722.
3. Inez-Ferreira TM, Mendoza L, Vilela R, et al. A Leishmania murine model to evaluate the immunomodulatory properties of Pythium insidiosum proteins. Heliyon 2017;3:e00278.
4. Ledur PC, Tondolo JSM, Jesus FPK, et al. Dendritic cells pulsed with Pythium insidiosum (1,3)(1,6)-beta-glucan, heat-inactivated zoospores and immunotherapy prime naive T cells to Th1 differentiation in vitro. Immunobiology 2018;223:294–299.
5. Weiblen C, Zanette RA, Ribeiro TC, et al. Intradermal injection of Pythium insidiosum protein antigens for improved diagnosis and treatment of pythiosis in an experimental model [published online ahead of print Sep 26, 2018]. Med Mycol doi: 10.1093/mmy/myy078.
6. Santurio JM, Leal AT, Leal AB, et al. Three types of immunotherapics against pythiosis insidiosi developed and evaluated. Vaccine 2003;21:2535–2540.
Advertisement